Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023-United States


#745905

60pages

DelveInsight

$ 3250

In Stock

DelveInsights Estrogen Receptor Positive (ER+) Breast Cancer - Market Insights, Epidemiology and Market Forecast-2023- US Reports provides an overview of the disease and global market size of the Estrogen Receptor Positive (ER+) Breast Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Estrogen Receptor Positive (ER+) Breast Cancer from 2013-2023. According to DelveInsight, the forecasted patient population of ER+ breast cancer will increase at a CAGR of 2.03% from 2015 to 2023 and the worldwide ER+ breast cancer market is estimated to be 2.86 billion by 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Note: This report will be delivered to the client in 48 hours

Scope
Report covers the disease overview, current treatment options, prescription drugs and emerging therapies.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States from 2013-2023.
It also provides Market size of Estrogen Receptor Positive (ER+) Breast Cancer for United States and forecasted Market size to 2023.